ADMS News and Press, Adamas Pharmaceuticals Inc. From 06/23/21

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Dise...

Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...

Biogen’s Alzheimer drug Aducanumab was approve amidst much debate. The Food and Drug Administration (FDA) grants accelerated approvals for drugs to treat serious illnesses for which there are no known, or very few, treatments. Was the drug to be marketed as Aduhelm incorrectly made avai...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, “Effects of GOCOVRI® (ama...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences: Chri...

Palm Beach, FL – May 12, 2021 – Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges during early childhood. Children show ASD-r...

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Adamas Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chief Financial O...

Adamas Pharma (ADMS): Q1 GAAP EPS of -$0.36 beats by $0.10.Revenue of $19.31M (+33.4% Y/Y) misses by $0.35M.Press Release For further details see: Adamas Pharma EPS beats by $0.10, misses on revenue

First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering med...